denufosol tetrasodium

09/01/2002 - "The enhanced metabolic stability and resultant increased duration of improved mucociliary clearance may confer significant advantages to INS37217 over other P2Y(2) agonists in the treatment of diseases such as cystic fibrosis."
08/15/2007 - "Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis."
12/01/2012 - "Long term effects of denufosol tetrasodium in patients with cystic fibrosis."
03/01/2011 - "Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function."
04/01/2005 - "Denufosol tetrasodium (INS37217) is a selective P2Y(2) agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF. "

06/01/2011 - "The P2Y2 receptor agonists (diquafosol tetrasodium and denufosol tetrasodium) are in the phase 3 of clinical trials for dry eye and cystic fibrosis, respectively. "

01/01/2003 - "Clinical trials are under way to test the effect of synthetic purinergic compounds, such as the P2Y(2) receptor agonist INS37217, on the progression of lung disease in patients with CF. "

11/01/2002 - "To evaluate the effects of subretinal and intravitreal delivery of INS37217, a P2Y(2) receptor agonist, on subretinal fluid reabsorption in experimentally induced retinal detachments in rabbits, and to characterize the effects of INS37217 on electroretinograms (ERG) in rabbits. "
11/01/2002 - "Effect of INS37217, a P2Y(2) receptor agonist, on experimental retinal detachment and electroretinogram in adult rabbits."
11/01/2002 - "To investigate the effects of INS37217, a synthetic P2Y(2) receptor agonist, on intracellular calcium signaling, electrophysiology, and fluid transport in vitro and on experimentally induced retinal detachment in rat eyes in vivo. "
11/01/2002 - "These results demonstrate that INS37217 enhances subretinal fluid reabsorption in experimental retinal detachment in rabbits and support the development of INS37217 for stimulating subretinal fluid reabsorption in conditions that result in retinal detachment or retinal edema."
11/01/2002 - "In vivo INS37217 enhances the rates of subretinal fluid reabsorption in experimentally induced retinal detachments in rats and may be therapeutically useful for treating a variety of retinal diseases that result in fluid accumulation in the subretinal space."

10/01/2003 - "These results support the use of INS37217 to help restore function after therapies that involve subretinal administration of drugs in animal models of retinal diseases."
11/01/2002 - "In vivo INS37217 enhances the rates of subretinal fluid reabsorption in experimentally induced retinal detachments in rats and may be therapeutically useful for treating a variety of retinal diseases that result in fluid accumulation in the subretinal space."